Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

MicroRNA Regulation Of Tumor-killing Viruses Avoids Unwanted Viral Pathology
Scientists have determined how to produce replication-competent viruses
generic viagra online
Reform Editorials Examine Rationed Care, Taxing Health Benefits
Wall Street Journal: A recent decision by CMS to end Medicare coverage of virtual colonoscopies is "a preview of how health care will be rationed when Democrats" create "a new "universal" health insurance entitlement for the middle class," a Journal editorial states. According to the editorial, the prospects of such a health system are "playing out in miniature in Medicare" where CMS has decided that offering an alternative to the traditional colonoscopy is "too pricey." The editorial states that the situation features "precisely the sort of complexity that the Democrats would prefer to ignore as they try to restructure health care" and use comparative effectiveness research to determine what works best for the majority of patients. According to the editorial, "The problem is that what "works best" isn"t the same for everyone." It continues that CMS "made the hard-and-fast choice that it was cheaper to cut [virtual colonoscopies] ... for all beneficiaries. If some patients are worse off, well, too bad." The editorial concludes that the situation is "merely a preview of the life-and-death decisions that will be determined by politics" if Democrats enact their ideal system (Wall Street Journal, 5/19).
News of the day
MS Society-Funded Study Investigates Experiences Of Partners Of People With MS
An MS Society-funded study has highlighted the impact that MS has on partners" lives and demonstrates the need for support and services for partners of people with MS.
Endocrinology

Quotient Bioresearch Acquires Edinburgh Clinical Research Facility From Charles River Laboratories And Forms Quotient Clinical

Quotient Bioresearch Limited ("Quotient"), a leading provider of drug development services, announces that it has acquired Charles River Laboratories" (Charles River) Edinburgh clinical research facility. This represents the sixth acquisition in approximately three years for Quotient. The Charles River facility, formerly Inveresk Clinical Research, will combine with Pharmaceutical Profiles, acquired by Quotient in December 2008, to form a new strategic business unit within Quotient - Quotient Clinical. With a long heritage in early development services, the Charles River Edinburgh clinical unit will combine with Pharmaceutical Profiles to offer a suite of integrated services stretching from First-in-Human (FIH) through to Phase 2a patient studies. Founded almost 20 years ago, the Edinburgh clinical unit is an industry leader in FIH studies. It was awarded Supplementary Accreditation status by the Medicines and Healthcare products Regulatory Agency (MHRA) in January 2009, demonstrating its experience and capabilities to conduct FIH trials for small molecules and biologics. Quotient Clinical will have a workforce of approximately 160 medical, scientific and clinical staff across the two facilities in Edinburgh and Nottingham. With an existing strong customer base in the United States, Europe and Japan, the principal focus of Quotient Clinical is to provide a unique and comprehensive range of early development services to a broad range of pharmaceutical and biotechnology customers. Paul Cowan, Chairman and CEO of Quotient comments, "The creation of Quotient Clinical represents the next step in expanding the range of specialised services we offer pharmaceutical and biotech customers worldwide. We are delighted to have completed the acquisition of the Charles River Edinburgh clinical facility. With the Inveresk heritage we are bringing a world-class facility and clinical experience to Quotient Clinical." Quotient Clinical will be headed by Mark Egerton, formerly Chief Executive Officer of Pharmaceutical Profiles. "We will continue to build on the innovative approaches we developed at Pharmaceutical Profiles to increase the effectiveness of early development processes. Combined with the Phase I/2a expertise of the Charles River Edinburgh clinical unit, our approach to integrating flexible drug product manufacture into clinical trials will enable us to deliver significant benefits to our customers." Quotient Bioresearch


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009